Taken together, substantial evidence from in vitro and in vivo studies, as well as from several human trials, indicates a strong relationship between cancer regression and various HR ligands, including H1R antagonists, H2R antagonists, and H4R agonists. This evidence concerns the gene HRH2 and cancer.